Navigation Links
Epizyme, Inc. to Present at Upcoming Conferences in September
Date:8/28/2013

CAMBRIDGE, Mass., Aug. 28, 2013 /PRNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, today announced its participation in upcoming September conferences.

  • Citi 8th Annual Biotech Day at the Mandarin Oriental Hotel in Boston, Mass. on Wednesday, September 4th
  • JMP Securities Biotech Day at the Langham Hotel in Boston, Mass. on Friday, September 6th at 11:00 a.m. ET.
  • Morgan Stanley Global Healthcare Conference at the Grand Hyatt in New York, N.Y. on Wednesday, September 11th at 8:00 a.m. ET. A live webcast will be available at this link or by visiting the Investor Center of the Epizyme website at www.epizyme.com. An archived replay of the webcast will be available on the Company's website for 30 days after the conference.
  • Stifel Nicolaus Healthcare Conference 2013 at the Four Seasons Hotel in Boston, Mass. on Thursday, September 12th at 2:05 p.m. ET. A live webcast will be available at this link or by visiting the Investor Center of the Epizyme website at www.epizyme.com. An archived replay of the webcast will be available on the Company's website for 30 days after the conference.
  • BioPharm America Conference at the Westin Boston Waterfront in Boston, Mass. on Tuesday, September 17th at 2:45 p.m. ET in a panel discussion titled "Partnering: Thinking beyond the deal."
  • Cancer Advance Boston at the Harvard Medical School in Boston, Mass. on Thursday, September 19th at 3:00 p.m. ET in a panel discussion titled "Redefining Cancer: Insights from Cancer Stem Cells, Epigenetics, Immunotherapy and More."
  • LES Annual Meeting at the Philadelphia Marriott Downtown in Philadelphia, Pa. on Monday, September 23rd at 12:15 p.m. ET to receive the 2013 LES Deal of Distinction Award in the Life Sciences Sector.
  • Discovery On Target 2013 at the Westin Boston Waterfront in Boston, Mass. on Tuesday, September 24th at 11:45 a.m. ET, presenting on targeting histone methyltransferases in cancer therapy.
  • BioCentury's NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel & Conference Center in New York, N.Y. on Friday, September 27th at 9:00 a.m. ET. A live webcast will be available at this link or by visiting the Investor Center of the Epizyme website at www.epizyme.com. An archived replay of the webcast will be available on the Company's website for 30 days after the conference.

About Epizyme, Inc.
Epizyme, Inc. is a clinical stage biopharmaceutical company creating personalized therapeutics for patients with genetically defined cancers. Epizyme has built a proprietary product platform that the company uses to create small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. HMTs are part of the system of gene regulation, referred to as epigenetics, that controls gene expression. Genetic alterations can result in changes to the activity of HMTs, making them oncogenic (cancer-causing). By focusing on the genetic drivers of cancers, Epizyme's targeted science seeks to match the right medicines with the right patients for a personalized approach to cancer treatment.

For more information, visit http://www.epizyme.com and connect with us on Twitter at @EpizymeRx.


'/>"/>
SOURCE Epizyme, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Epizyme, Inc. to Present at Wedbush Securities Life Sciences Management Access Conference in August
2. Epizyme, Inc. to Webcast Conference Call Discussing Second Quarter 2013 Financial Results on July 31, 2013
3. Epizyme, Inc. Announces Pricing of Initial Public Offering
4. Epizyme, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Genocea Biosciences Selected To Present Late-Breaking Oral Presentation At ICAAC 2013
6. BioLineRx to Present at 15th International Celiac Disease Symposium
7. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
8. Affordable IVF Presents A Free Information Evening
9. Luminex Corporation To Present At Morgan Stanley Global Healthcare Conference
10. Thoratec Presentation At Morgan Stanley 2013 Health Care Conference To Be Webcast
11. Zimmer Holdings to Present at UBS Best of Americas Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... 2017  New York City-based market research firm Kalorama Information ... aware of.  From new products to new costs, to the ... recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact Moment Arriving ... the impact the growing population and, to a more extreme ...
(Date:7/11/2017)... , July 11, 2017  The global market ... revenues of approximately $394.1 million in 2016.  Although in ... of solid growth, in particular as a result of ... practice, and the recent introduction of a significant number ... for less-invasive testing of tumor biomarkers to guide treatment ...
(Date:7/10/2017)... Md. , July 10, 2017 The ... non-animal test methods, is the recipient of a VITROCELL® ... the PETA International Science Consortium. The device, which is ... used to expose human lung cells to airborne test ... IIVS will use the VITROCELL® system for testing combustible ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... ... selected to renovate and improve the Ramsey County Medical Examiners Facility located in ... Hospital, the $2.5 million project is scheduled to start in late 2017/early 2018. ...
(Date:7/21/2017)... ... 21, 2017 , ... Bernard R. Bach, Jr., MD, orthopaedic surgeon at Rush ... Society of Sports Medicine (AOSSM) , received the 2017 Robert E. Leach Sports Medicine ... Canada. This prestigious award is given annually to honor those who have made a ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... 4th-year medical students improve their chances of acceptance to a residency in a ... who have earned degrees outside the U.S. , According to data released by ...
(Date:7/21/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 21, ... ... with over 80% follow-up at 10 years, researchers from the Multicenter Orthopaedics Outcome ... knee-related quality of life a decade after surgery, though activity levels decline over ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ChenMed ... MD, has joined JenCare Senior Medical Center as Richmond Chief Medical Officer. ... School of Medicine, and Associate Chief Medical Officer of Ambulatory Services for the UVA ...
Breaking Medicine News(10 mins):